Answer
Yes, durvalumab (Imfinzi) can cause immune-mediated type 1 diabetes mellitus that first presents as diabetic ketoacidosis, which can be fatal if not detected early.
Sources for this answer
- IMFINZI 50 mg/mL concentrate for solution for infusionAstraZeneca UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 38Document updated
Sources checked